CareDx, Inc (CDNA)
- Previous Close
7.56 - Open
7.62 - Bid 7.52 x 400
- Ask 7.57 x 200
- Day's Range
7.42 - 7.84 - 52 Week Range
4.80 - 12.93 - Volume
488,543 - Avg. Volume
815,038 - Market Cap (intraday)
391.445M - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-3.54 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.40
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
caredx.com635
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CDNA
Performance Overview: CDNA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDNA
Valuation Measures
Market Cap
391.45M
Enterprise Value
190.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.45
Price/Book (mrq)
1.50
Enterprise Value/Revenue
0.68
Enterprise Value/EBITDA
-2.24
Financial Highlights
Profitability and Income Statement
Profit Margin
-67.88%
Return on Assets (ttm)
-12.88%
Return on Equity (ttm)
-54.98%
Revenue (ttm)
280.32M
Net Income Avi to Common (ttm)
-190.28M
Diluted EPS (ttm)
-3.54
Balance Sheet and Cash Flow
Total Cash (mrq)
235.42M
Total Debt/Equity (mrq)
13.10%
Levered Free Cash Flow (ttm)
12.85M